Agreement signed for Alkindi® and future pipeline products with Diurnal Group plc

Consilient Health are pleased to announce the signing of a marketing and distribution agreement with Diurnal Group plc for Alkindi®, and future pipeline endocrinology products for diseases of cortisol deficiency, for the BeNeLux region. Consilient Health will, once again, work with our trusted partner in BeNeLux, GoodLife Pharma, to market and distribute Alkindi® and future products covered by this agreement.

Diurnal is a specialty pharma company targeting patient needs in chronic endocrine (hormonal) diseases. Diurnal’s CEO, Martin Whitaker, commented, “this additional marketing and distribution agreement further validates the quality of our products and immediately broadens the future availability of Alkindi® in Europe. Our new partners are well placed to distribute our products in their markets and we believe that our strategy and global ambitions are aligned with them through this collaboration.”

Ahmed Al-Derzi, Consilient Health’s CEO added, “Consilient Health are delighted to form this partnership with Diurnal and to work with our BeNeLux partners, Goodlife Pharma, and Diurnal to bring Alkindi® and future products to patients in the BeNeLux region. Alkindi® and our partnership with Diurnal enables us to further broaden our growing offering to endocrinology specialists and their patients.”

View more news and events